Gene therapy heals wounds in rare skin disease?
NCT ID NCT04213261
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a gene therapy called FCX-007 for people with recessive dystrophic epidermolysis bullosa, a rare disease that causes fragile skin and painful blisters. The therapy uses the patient's own skin cells, genetically corrected to produce collagen, and injects them into wounds. The study compares treated wounds to untreated ones in just 6 participants, looking for complete healing by 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FCX-007 (dabocemagene autoficel) – a gene-corrected skin cell therapy
What this could lead to
If it works, this could provide a way to heal chronic wounds in people with a severe skin blistering disease, improving quality of life.
What could go wrong
This is a very small early-phase trial with only 6 people, so results may not apply to everyone. The treatment involves injections and there is a risk of immune reactions or the wounds not healing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Dell Children's Medical Group
Austin, Texas, 78723, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Solutions Through Advanced Research, Inc.
Jacksonville, Florida, 32256, United States
-
Stanford University
Stanford, California, 94305, United States